1. Home
  2. ALMU vs IFRX Comparison

ALMU vs IFRX Comparison

Compare ALMU & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeluma Inc.

ALMU

Aeluma Inc.

HOLD

Current Price

$16.20

Market Cap

293.1M

Sector

Technology

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.70

Market Cap

303.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALMU
IFRX
Founded
2019
2007
Country
United States
Germany
Employees
14
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.1M
303.4M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ALMU
IFRX
Price
$16.20
$1.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$24.67
$6.25
AVG Volume (30 Days)
484.4K
972.4K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.49
N/A
Revenue Next Year
$60.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.24
$0.74
52 Week High
$31.79
$2.95

Technical Indicators

Market Signals
Indicator
ALMU
IFRX
Relative Strength Index (RSI) 43.65 36.69
Support Level $14.28 $1.54
Resistance Level $17.64 $1.71
Average True Range (ATR) 1.27 0.12
MACD 0.20 -0.02
Stochastic Oscillator 57.54 10.75

Price Performance

Historical Comparison
ALMU
IFRX

About ALMU Aeluma Inc.

Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: